I own stock in both Inovio (INO) and Dendreon (DNDN). Both reported Q3 2013 results on Tuesday.
You can read my notes on the results and analyst conferences at:
Inovio Q3 2013
Dendreon Q3 2013
Inovio had a good quarter on many fronts, probably justifying the huge leap in its stock price in the past year. It is a development-stage vaccine company, but is in partnership with Roche and apparently has the ability to make vaccines for just about anything, including cancer. Nevertheless, it has not yet had any FDA approvals, and the risk of failure should be taken into account if you are thinking about investing.
Dendreon continues to struggle. Although Q3 revenue from Provenge was disappointing, they said that October was the best month for enrollments in 2013. So could Q4 come in at $80 million of revenue? No guidance was given, but between the approval in Europe and the
Dendreon's failure to capitalize on the first FDA-approved immunotherapy for cancer, Provenge for prostate cancer, had cast investor doubt on the entire immunotherapy for cancer field. In response to a question from an analyst, Inovio's CEO said if its therapy works and gains approval it would not have the high Cost of Goods Sold (COGS) that has plagued Dendreon. Inovio's therapy is more like its anti-viral vaccines, whereas Dendreon's therapy requires extracting blood from patients, activating T-cells, and then re-infusing the patients. Even at $100,000 per therapy Dendreon is losing money.
I am busy, busy, busy, so I don't know when I'll be able to write up these companies for Seeking Alpha. My last articles on them need updating, but there is still good background material in them:
Inovio's Price Spike and the Future of DNA Vaccines [August 17, 2013]
Dendreon Revenue and Cost Trends [August 13, 2013]
Keep diversified!
Showing posts with label immunotherapy. Show all posts
Showing posts with label immunotherapy. Show all posts
Wednesday, November 13, 2013
Saturday, April 13, 2013
Provenge Could Be Combined with Other Prostate Cancer Therapies
Provenge is the only immune therapy approved by the FDA for the treatment of prostate cancer. It is an expensive treatment, about $100,000 per patient, and it is only approved for asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. In other words, once prostate cancer has become both malignant and keeps growing despite testosterone being artificially lowered, and before it has become painful.
According to its Seattle-based maker Dendreon (DNDN) , Provenge will "jumpstart your immune system to fight advanced prostate cancer." Unfortunately some prostate cancer has its own tricks for defeating the immune system. As a result, in clinical trials, compared to untreated patients, Provenge therapy extends life by a median (50% of men don't get this much benefit, 50% get more) of 4.2 months. Some lucky men live much longer, including some who have now survived for years.
Finding out why some men don't respond well, and helping all prostate cancer patients live longer, is now a major medical science question. One group of doctors who may have an answer is led by Samir N. Khleif, MD, director or the Georgia Regent University Cancer Center. He believes there is good science indicating cyclophasphamide and CT-011 both inhibit prostate cancer's ability to circumvent both the body's natural immune system and therapies like Provenge.
A trial is planned in which men with metastatic prostate cancer will also take either or both cyclophasphamide and CT-011 along with Provenge. While this is an exciting theory, it should be emphasized that it will likely be a couple of years before the results are known. Then, most likely, the FDA would require a larger Phase III trial to be successful before approving the combined therapy. [See also Interview with Samir N. Khleif, MD in Renal & Urology News]
Prostate cancer is quite common in older men and generally is not a death sentence: In the U.S. 240,000 men are diagnosed annually, and about 30,000 die. Most prostate cancer victims die of some other cause, and it is difficult to predict which individuals will see their disease progress to being metastatic and castrate resistant. However, at that point it tends to be deadly. There is a broad debate over whether earlier interventions like surgery and radiation are overdone. Those who favor early treatment believe it cuts down on the number who progress to deadly disease. Those who oppose early treatment point to its cost, the low likelihood of progression being the cause of death in older men, and the complications from treatment (loss of control and occasional deaths from surgery.) Even lowering testosterone levels has side effects men don't like.
David Crawford, MD, is one of the growing number of physicians who believes that the answer may be in sequencing therapies for late-stage prostate cancer patients. He points out that in the last 3 years several therapies that are proven to help have finally been approved by the FDA, and more may be on the way. In addition to Provenge, we now have Zytiga which lowers testosterone more than previous drugs could, and Xtandi, which is an androgen receptor antagonist.
Doctor Crawford believes that for cancer in general multiple therapies have been more successful than single therapies. This is partly because cancers can develop defenses against therapies over time. By attacking prostate cancer at one, or in quick succession, with the newer therapies, Crawford believes patients will see better results. Trials are underway to determine if there is a preferred sequence for prostate cancer. [See Optimal Sequencing of the New Prostate Cancer Drugs in Renal & Urology News]
Currently doctors are divided into two camps. Some favor either Zytiga or Xtandi first because they act quickly to reduce hormone levels. Others favor Provenge first because the immune system acts over time and the cancer at this stage is already
The consensus in the community seems to be moving towards giving both types of therapy as soon as possible. As with Provenge, neither Zytiga nor Xtandi are cures, but instead, on a statistical basis, prolong the lives of the patients who take them. Xtandi prolongs life by a median of 5 months, slightly longer than the Provenge median.
Disclaimer: I own Dendreon (DNDN) stock and will not trade the stock for 7 days after the publication of this report.
William P. Meyers
See also: www. dendreon.com
My main Dendreon notes page.
According to its Seattle-based maker Dendreon (DNDN) , Provenge will "jumpstart your immune system to fight advanced prostate cancer." Unfortunately some prostate cancer has its own tricks for defeating the immune system. As a result, in clinical trials, compared to untreated patients, Provenge therapy extends life by a median (50% of men don't get this much benefit, 50% get more) of 4.2 months. Some lucky men live much longer, including some who have now survived for years.
Finding out why some men don't respond well, and helping all prostate cancer patients live longer, is now a major medical science question. One group of doctors who may have an answer is led by Samir N. Khleif, MD, director or the Georgia Regent University Cancer Center. He believes there is good science indicating cyclophasphamide and CT-011 both inhibit prostate cancer's ability to circumvent both the body's natural immune system and therapies like Provenge.
A trial is planned in which men with metastatic prostate cancer will also take either or both cyclophasphamide and CT-011 along with Provenge. While this is an exciting theory, it should be emphasized that it will likely be a couple of years before the results are known. Then, most likely, the FDA would require a larger Phase III trial to be successful before approving the combined therapy. [See also Interview with Samir N. Khleif, MD in Renal & Urology News]
Prostate cancer is quite common in older men and generally is not a death sentence: In the U.S. 240,000 men are diagnosed annually, and about 30,000 die. Most prostate cancer victims die of some other cause, and it is difficult to predict which individuals will see their disease progress to being metastatic and castrate resistant. However, at that point it tends to be deadly. There is a broad debate over whether earlier interventions like surgery and radiation are overdone. Those who favor early treatment believe it cuts down on the number who progress to deadly disease. Those who oppose early treatment point to its cost, the low likelihood of progression being the cause of death in older men, and the complications from treatment (loss of control and occasional deaths from surgery.) Even lowering testosterone levels has side effects men don't like.
David Crawford, MD, is one of the growing number of physicians who believes that the answer may be in sequencing therapies for late-stage prostate cancer patients. He points out that in the last 3 years several therapies that are proven to help have finally been approved by the FDA, and more may be on the way. In addition to Provenge, we now have Zytiga which lowers testosterone more than previous drugs could, and Xtandi, which is an androgen receptor antagonist.
Doctor Crawford believes that for cancer in general multiple therapies have been more successful than single therapies. This is partly because cancers can develop defenses against therapies over time. By attacking prostate cancer at one, or in quick succession, with the newer therapies, Crawford believes patients will see better results. Trials are underway to determine if there is a preferred sequence for prostate cancer. [See Optimal Sequencing of the New Prostate Cancer Drugs in Renal & Urology News]
Currently doctors are divided into two camps. Some favor either Zytiga or Xtandi first because they act quickly to reduce hormone levels. Others favor Provenge first because the immune system acts over time and the cancer at this stage is already
The consensus in the community seems to be moving towards giving both types of therapy as soon as possible. As with Provenge, neither Zytiga nor Xtandi are cures, but instead, on a statistical basis, prolong the lives of the patients who take them. Xtandi prolongs life by a median of 5 months, slightly longer than the Provenge median.
Disclaimer: I own Dendreon (DNDN) stock and will not trade the stock for 7 days after the publication of this report.
William P. Meyers
See also: www. dendreon.com
My main Dendreon notes page.
Labels:
cost,
David Crawford,
Dendreon,
DNDN,
immunotherapy,
prostate cancer,
Samir N. Khleif,
testosterone,
treatment,
Xtandi,
Zytiga
Monday, December 17, 2012
Inovio Positive Vaccine Data Releases
Inovio (INO) is a micro-cap biotechnology company that is developing innovative vaccines and delivery systems. It has a market capitalization, today, of $71 million and the stock price closed at $0.51. (versus 52wk High/Low $0.90/$0.37; volatility is high)
Inovio's vaccines are aimed at difficult to treat viruses that typically exist in multiple strains. This means a specific traditional vaccine has to be developed to protect people from each strain. That takes times, and a new strain can emerge and infect a global population faster than a traditional vaccine can be developed. Inovio's SynCon vaccines are believed to provide cross-protection against multiple strains.
Results have been coming in on a regular basis from trials. In September Inovio announced an open-label Phase I study of its universal H1N1 influenza vaccine provoked immune responses "against some of the most prevalent strains of H1N! influenza from the past 100 years."
One veterinary subsidiary of Inovio reported its improved LifeTide DNA plasmid therapy for pigs to produces more piglets per litter, with higher birth weights, and at a lower dosage than the original version. A separate subsidiary in New Zealand received regulatory permission to market the therapy in October.
Also in October results from a VGX-3100 vaccine trial for HPV (human papillomavirus) showed 100% of 18 patients in the trial showed antigen-specific antibody response, while 78% showed T-cell responses. A phase II trial now underway will determine if the immune responses are able to reverse disease progression to cervical cancer.
In pre-clinical trials Inovio demonstrated that its electroporation technique for introducing its vaccines to skin using minimal invasion "induces robust cellular and humoral immune responses."
November was a busy month. First Inovio Hepatitis B (HPV) vaccine demonstrated the potential to clear HBV from the liver in mice in a pre-clinical trial. Another preclinical study showed T-cell immune response in Cytomegalovirus (CMV).
On December 6th positive Phase II interim results were reported in the leukemia trial. This could lead to treating CML (chronic myelogenous leukemia) with a vaccine. The results are from just 8 patients, with 14 patients currently enrolled and a total of 31 to be studied in the full trial. In addition to showing the vaccine to be safe. Patients received six does of two DNA vaccines at four week intervals. Tests showed T cells and leukemia antibodies were generated. Note, however, no data was released as to whether the patients responded to the therapy by delays in progression or the other usual indicators. In addition to CML, some of the patients to be enrolled will be suffering from AML (acute myeloid leukemia, a more common variety than CML).
Most recently, on December 10th interim Phase I results for H1N1 flu vaccine given to elderly patients were announced. 50 patients were in the trial, with two sets of 20 receiving the vaccine on differing schedules and 10 control subjects who received the traditional seasonal flu vaccine. Immune responses registered at 40% for the Inovio vaccine, double the rate of 20% responding to the traditional vaccine. It was previously known that elderly patients tend to not gain immunity from standard flu vaccines.
What is innovative about Inovio vaccines? They are DNA vaccines. Traditional vaccines consist of weakened or dead viruses or their protein coatings. DNA vaccines need to be inserted into cells (instead of into the bloodstream), but once there can trigger both antibody and T-cell immune responses. To insert the vaccines into cells Inovio uses an electroporation device it developed and has successfully tested. Inovio, in fact, resulted from the merger of a vaccine company and an electroporation developer.
It is important to note that all of the new data is from early-stage trials. To receive FDA approval for commercial sales of a therapy typically two successful Phase III trials are required. Inovio Pharmaceuticals is a developmental stage company with all the risks and uncertainties inherent in that status.
In addition to the recent news, Inovio has a Hepatitis C vaccine in a Phase II trial, and an HIV vaccine in Phase I. It has more cancer vaccine candidates: prostate in preclinical, and a breast/lung/prostate cancer trial in Phase I.
Despite the risk of failure common to all new biotechnology, I believe Inovio is more likely than not to be worth far more in a few years than it is now. Inovio has many shots on goal. Only one vaccine would need to be approved by the FDA to make Inovio a highly-valuable company.
Another risk for investors is that Inovio is likely to need to raise cash to complete its program of demonstrating the effectiveness of its vaccines, and to commercialize them. However, as of the end of Q3, Inovio had $15 million in cash, and some of the trials are being conducted, or paid for, by partners.
Disclaimer: I am long INO. I will not trade INO for 7 days following the publication of this article.
Keep diversified! You should also take a good close look at inovio.com and SEC documents before risking your capital.
Inovio's vaccines are aimed at difficult to treat viruses that typically exist in multiple strains. This means a specific traditional vaccine has to be developed to protect people from each strain. That takes times, and a new strain can emerge and infect a global population faster than a traditional vaccine can be developed. Inovio's SynCon vaccines are believed to provide cross-protection against multiple strains.
Results have been coming in on a regular basis from trials. In September Inovio announced an open-label Phase I study of its universal H1N1 influenza vaccine provoked immune responses "against some of the most prevalent strains of H1N! influenza from the past 100 years."
One veterinary subsidiary of Inovio reported its improved LifeTide DNA plasmid therapy for pigs to produces more piglets per litter, with higher birth weights, and at a lower dosage than the original version. A separate subsidiary in New Zealand received regulatory permission to market the therapy in October.
Also in October results from a VGX-3100 vaccine trial for HPV (human papillomavirus) showed 100% of 18 patients in the trial showed antigen-specific antibody response, while 78% showed T-cell responses. A phase II trial now underway will determine if the immune responses are able to reverse disease progression to cervical cancer.
In pre-clinical trials Inovio demonstrated that its electroporation technique for introducing its vaccines to skin using minimal invasion "induces robust cellular and humoral immune responses."
November was a busy month. First Inovio Hepatitis B (HPV) vaccine demonstrated the potential to clear HBV from the liver in mice in a pre-clinical trial. Another preclinical study showed T-cell immune response in Cytomegalovirus (CMV).
On December 6th positive Phase II interim results were reported in the leukemia trial. This could lead to treating CML (chronic myelogenous leukemia) with a vaccine. The results are from just 8 patients, with 14 patients currently enrolled and a total of 31 to be studied in the full trial. In addition to showing the vaccine to be safe. Patients received six does of two DNA vaccines at four week intervals. Tests showed T cells and leukemia antibodies were generated. Note, however, no data was released as to whether the patients responded to the therapy by delays in progression or the other usual indicators. In addition to CML, some of the patients to be enrolled will be suffering from AML (acute myeloid leukemia, a more common variety than CML).
Most recently, on December 10th interim Phase I results for H1N1 flu vaccine given to elderly patients were announced. 50 patients were in the trial, with two sets of 20 receiving the vaccine on differing schedules and 10 control subjects who received the traditional seasonal flu vaccine. Immune responses registered at 40% for the Inovio vaccine, double the rate of 20% responding to the traditional vaccine. It was previously known that elderly patients tend to not gain immunity from standard flu vaccines.
What is innovative about Inovio vaccines? They are DNA vaccines. Traditional vaccines consist of weakened or dead viruses or their protein coatings. DNA vaccines need to be inserted into cells (instead of into the bloodstream), but once there can trigger both antibody and T-cell immune responses. To insert the vaccines into cells Inovio uses an electroporation device it developed and has successfully tested. Inovio, in fact, resulted from the merger of a vaccine company and an electroporation developer.
It is important to note that all of the new data is from early-stage trials. To receive FDA approval for commercial sales of a therapy typically two successful Phase III trials are required. Inovio Pharmaceuticals is a developmental stage company with all the risks and uncertainties inherent in that status.
In addition to the recent news, Inovio has a Hepatitis C vaccine in a Phase II trial, and an HIV vaccine in Phase I. It has more cancer vaccine candidates: prostate in preclinical, and a breast/lung/prostate cancer trial in Phase I.
Despite the risk of failure common to all new biotechnology, I believe Inovio is more likely than not to be worth far more in a few years than it is now. Inovio has many shots on goal. Only one vaccine would need to be approved by the FDA to make Inovio a highly-valuable company.
Another risk for investors is that Inovio is likely to need to raise cash to complete its program of demonstrating the effectiveness of its vaccines, and to commercialize them. However, as of the end of Q3, Inovio had $15 million in cash, and some of the trials are being conducted, or paid for, by partners.
Disclaimer: I am long INO. I will not trade INO for 7 days following the publication of this article.
Keep diversified! You should also take a good close look at inovio.com and SEC documents before risking your capital.
Labels:
CMV,
cytomegalovirus,
DNA,
electroporation,
flu,
hepatitis C,
immunotherapy,
influenza,
INO,
Inovio,
leukemia,
vaccines
Tuesday, May 3, 2011
Dendreon On Plan for Q1, full 2011
Yesterday Dendreon held its analyst conference call and released its Q1 2011 results. The key take away is that everything is going according to plan. For a company that spent years in the wilderness wondering if they would ever get FDA approval of Provenge active immunotherapy for prostate cancer, making and staying on plan seems to be an obsession.
Dendreon is a long way from profitability as it ramps up its Provenge system. The GAAP net loss for the quarter was $111.8 million, or $0.77 per share on revenue of $28 million.
Provenge is a process in which a prostate cancer patient's blood is activated to get the immune system to attack the cancer. Some blood is withdrawn at a clinic, flown to the New Jersey manufacturing facility, treated at a workstation, and then flown back to be infused in the patient. The initial launch was done with just 12 workstations. In Q1 the FDA approved an additional 36 workstations for New Jersey, but the ramp up did not come until near the end of the quarter. In April, however, more of the machines were working, so the revenue run rate grew to $15 million for the month. On average in Q2 Dendreon expects to run 24 machines.
The new machines can take on a higher flow of patients, which in turn means allowing more doctors and clinics to provide the therapy. Two additional manufacturing facilities, near Los Angeles and Atlanta, hope to be approved by the FDA this summer and fall.
Guidance remains that for full 2011 revenue will run $350 to $400 million. Half that will come in Q4, if workstations in all 3 facilities are available. My read on that is not that $200 million per quarter is the top run rate. All machines will not be online at the beginning of Q4 and their will be room for higher run rates as the machines are made more efficient and run multiple shifts per day.
Apparently men with (the appropriate stage of) prostate cancer want to try Provenge, which has few side effects.
Global expansion will take years, but Dendreon is already spending money to get ready for a European launch. A global trial of Provenge will also get underway this year.
See my Dendreon Analyst Call for Q1 2011 notes more detail.
See also: Dendreon
And keep diversified!
Dendreon is a long way from profitability as it ramps up its Provenge system. The GAAP net loss for the quarter was $111.8 million, or $0.77 per share on revenue of $28 million.
Provenge is a process in which a prostate cancer patient's blood is activated to get the immune system to attack the cancer. Some blood is withdrawn at a clinic, flown to the New Jersey manufacturing facility, treated at a workstation, and then flown back to be infused in the patient. The initial launch was done with just 12 workstations. In Q1 the FDA approved an additional 36 workstations for New Jersey, but the ramp up did not come until near the end of the quarter. In April, however, more of the machines were working, so the revenue run rate grew to $15 million for the month. On average in Q2 Dendreon expects to run 24 machines.
The new machines can take on a higher flow of patients, which in turn means allowing more doctors and clinics to provide the therapy. Two additional manufacturing facilities, near Los Angeles and Atlanta, hope to be approved by the FDA this summer and fall.
Guidance remains that for full 2011 revenue will run $350 to $400 million. Half that will come in Q4, if workstations in all 3 facilities are available. My read on that is not that $200 million per quarter is the top run rate. All machines will not be online at the beginning of Q4 and their will be room for higher run rates as the machines are made more efficient and run multiple shifts per day.
Apparently men with (the appropriate stage of) prostate cancer want to try Provenge, which has few side effects.
Global expansion will take years, but Dendreon is already spending money to get ready for a European launch. A global trial of Provenge will also get underway this year.
See my Dendreon Analyst Call for Q1 2011 notes more detail.
See also: Dendreon
And keep diversified!
Labels:
analyst conferences,
Dendreon,
FDA,
immunotherapy,
prostate cancer,
Provenge,
revenues
Friday, January 7, 2011
Provenge Prostate Cancer European Availability Planned
All fifteen Medicare regions and 80% of private payers have now approved Provenge (sipuleucel-T) for (asymptomatic or minimally symptomatic metastatic hormone refractory) prostate cancer for reimbursement. Expects to increase capacity by a factor of ten in 2011; should have 450 infuser sights by the end of the year; already hired 100 sales people.
$48 million total Provenge revenue in 2010, with about $25 million in Q4. $350 to $400 million revenue expected in full 2011, with about half of that coming in Q4. $280 million cash balance at the end of the year. GAAP loss of $310 million to $350 million for 2011; non-gAAP loss of $230 to $270 million.
Europe will be the first target for further Provenge approval. Believes addressable market would be about the same size as in the United States. There is a major unmet medical need there. After meeting with the European regulatory agency (EMA), IMPACT and other data already available should be sufficient to get European regulatory approval. Will engage a contact manufacturing organization for initial Provenge supply in Europe. Will also use this for trials for earlier-stage prostate cancer. But will concurrently build a Dendreon facility in Germany in 2011.
EMA decision would be possible in 2013. Reimbursement must be achieved nation by nation, and there are challenges. But as overall survival is the gold standard for European payers, and overall costs are actually reasonable for Provenge. Cancer therapy prices are largely similar in Europe to the U.S.
$125 million will be spent in 2011 to support American and European expansion, with about half attributed to capital expense and half to operating expense. Will require more capital for the European expansion.
ACI (autologous cellular immunotherapy) platform now includes an investigational product Nuvenge (DN24-02) for invasive bladder cancer. This is a highly immuno-responsive. Will be a randomized Phase II study for patients with HER2+ invasive transitional cell carcinoma of the bladder following cystectomy. Patients with advanced cancer have few good treatment options at present. Endpoint would be overall survival.
Q&A
Plans are for one plant in Europe? It is not necessarily our expectation that we would only ever have one. If reimbursements are approved, we could build more plants.
The European, or global, study would not be to support the regulatory filing. It would be to provide evidence of the efficacy of Provenge for earlier stages of prostate cancer.
Trajectory for expanding infusion centers? Started with 50, finished with slightly more. 450 should be available in Q4. The launch centers had been in previous clinical trials, many in very small clinics. Some of the new centers are much larger in terms of numbers of patients. First additional capacity should come on line in New Jersey, corresponding to about a third of the new centers also starting up.
Europe, maximum capacity for German facility? Seen as very similar to the Los Angeles and Atlanta facilities in design and capacity. Because population density is higher, the center could serve all of the EU countries.
The Contract Manufacturing Facility in Europe would support the new study there. The new Dendreon facility should be ready around the time of approval.
Any message change on prostate cancer since Provenge approval? We are in a golden era now for prostate cancer. Good data sets are coming out for drugs for the chemo-sensative prostate cancers.
Still 2000 patients for 2010? That was for middle of the year, which would be in July 2011.
New Jersey expansion should come online some time in March, but new clinics are already ready to go when that capacity does come online.
How will you raise money, equity or debt? Looking at the alternatives, no decision yet.
CMOs capable of making provenge? Yes, we used 2 CMOs in the U.S. before we began manufacturing our own.
See the accompanying press release: Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
$48 million total Provenge revenue in 2010, with about $25 million in Q4. $350 to $400 million revenue expected in full 2011, with about half of that coming in Q4. $280 million cash balance at the end of the year. GAAP loss of $310 million to $350 million for 2011; non-gAAP loss of $230 to $270 million.
Europe will be the first target for further Provenge approval. Believes addressable market would be about the same size as in the United States. There is a major unmet medical need there. After meeting with the European regulatory agency (EMA), IMPACT and other data already available should be sufficient to get European regulatory approval. Will engage a contact manufacturing organization for initial Provenge supply in Europe. Will also use this for trials for earlier-stage prostate cancer. But will concurrently build a Dendreon facility in Germany in 2011.
EMA decision would be possible in 2013. Reimbursement must be achieved nation by nation, and there are challenges. But as overall survival is the gold standard for European payers, and overall costs are actually reasonable for Provenge. Cancer therapy prices are largely similar in Europe to the U.S.
$125 million will be spent in 2011 to support American and European expansion, with about half attributed to capital expense and half to operating expense. Will require more capital for the European expansion.
ACI (autologous cellular immunotherapy) platform now includes an investigational product Nuvenge (DN24-02) for invasive bladder cancer. This is a highly immuno-responsive. Will be a randomized Phase II study for patients with HER2+ invasive transitional cell carcinoma of the bladder following cystectomy. Patients with advanced cancer have few good treatment options at present. Endpoint would be overall survival.
Q&A
Plans are for one plant in Europe? It is not necessarily our expectation that we would only ever have one. If reimbursements are approved, we could build more plants.
The European, or global, study would not be to support the regulatory filing. It would be to provide evidence of the efficacy of Provenge for earlier stages of prostate cancer.
Trajectory for expanding infusion centers? Started with 50, finished with slightly more. 450 should be available in Q4. The launch centers had been in previous clinical trials, many in very small clinics. Some of the new centers are much larger in terms of numbers of patients. First additional capacity should come on line in New Jersey, corresponding to about a third of the new centers also starting up.
Europe, maximum capacity for German facility? Seen as very similar to the Los Angeles and Atlanta facilities in design and capacity. Because population density is higher, the center could serve all of the EU countries.
The Contract Manufacturing Facility in Europe would support the new study there. The new Dendreon facility should be ready around the time of approval.
Any message change on prostate cancer since Provenge approval? We are in a golden era now for prostate cancer. Good data sets are coming out for drugs for the chemo-sensative prostate cancers.
Still 2000 patients for 2010? That was for middle of the year, which would be in July 2011.
New Jersey expansion should come online some time in March, but new clinics are already ready to go when that capacity does come online.
How will you raise money, equity or debt? Looking at the alternatives, no decision yet.
CMOs capable of making provenge? Yes, we used 2 CMOs in the U.S. before we began manufacturing our own.
See the accompanying press release: Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
Wednesday, June 24, 2009
Dendreon, The Glory and the Dream
A moment ago Dendreon's (DNDN) had a stock price of $24.70 and a market capitalization of $2.85 billion. At this moment Dendreon does not have a product approved for sale by the FDA. I would never buy such a company. Yet I own the stock, which I bought years ago when almost every other biotechnology analyst thought Dendreon's Provenge (sipuleucel-T) therapy would be summarilly rejected by the FDA.
At my Dendreon analyst conferences page you can find all of my past articles about the positives and negatives of DNDN's prospects. Before the latest data came in I recommended it only as a stock for risk-takers who know how to hedge risk. I have not written anything new since the latest data was announced. Good data has lowered the risk while increasing the stock price, which increases potential down side if something goes wrong. So a different class of investors are probably buying it recently.
Here, as implied by the title, I want to look at the best-case scenario, where in a few years investors might wish they had gotten in when the market cap was only in the low billions. In this scenario we go beyond the approval of Provenge for late-state metastatic, androgen-independent prostate cancer by the FDA some time in 2010. I believe approval by the FDA has already been fully-factored into the current price, at least by conservative, rational investors.
Provenge is an immunotherapy. There is no reason to think that its use cannot be extended to any prostate cancer that has antigen presenting cells (APCs) that can be activated with PAP (prostatic acid phosphatase). Or some similar method of stimulating a T cell response against prostate cancer cells, which is what Provenge does.
So while selling Provenge after FDA approval, the short term strategy for Dendreon is most likely to conduct more clinical trials that, if successful, will allow label extensions. Given Provenge's safety profile so far, and its ease-of-use (it requires just 3 infusions), it may become a blockbuster if it proves effective with earlier stages of prostate cancer.
Meanwhile, there is the pipeline Dendreon has already established. This includes Lapuleucel-T for breast, ovarian, and colon cancer. CEA for breast, lung, and colon cancer. And CA-9 for kidney, colon and cervical cancer. All three are immunotherapies, and only Lauleucel-T has started clinical trials. CEA and CA-9 are joined by Trp-p8 in being preclinical (lab/animal testing stage). The later is a small-molecule prostate therapy. I suppose they know a lot about prostate cancer now, and wanted a small-molecule as a hedge against the limitations of immunotherapy.
Developing a pipeline is a very long term process. It will probably take years to get any of the drugs already in the pipeline through FDA approval, and that is assuming the data is good. Figure 5 years for another approval, maybe 3 years under the most accelerated scenario. I know; most investors can't think that long term.
But look at the best case scenario ten years out. Dendreon could, by then, have brought out immunotherapies for all the major cancer types.
And therein lies the glory and the dream. Given the complexity of the human body, the immune system, and cancers, it is highly unlikely that immunotherapy will replace other cancer therapies. But given its safety (if it proves to be safe long-term), there is no reason not to try it on any and every cancer patient.
Just a hint of that scenario breaths life into Dendreon's stock price. We are talking truly big money. Others will accelerate their immunotherapy efforts, but Dendreon has a lead and will be generating revenues from Provenge that can be used to bring new immunotherapies to market.
What Dendreon owns is not just Provenge. It owns, and has protected with patents, a new type of technology. If the technology really works, Dendreon is not just a company. It is an industry in the making.
Keep diversified!
At my Dendreon analyst conferences page you can find all of my past articles about the positives and negatives of DNDN's prospects. Before the latest data came in I recommended it only as a stock for risk-takers who know how to hedge risk. I have not written anything new since the latest data was announced. Good data has lowered the risk while increasing the stock price, which increases potential down side if something goes wrong. So a different class of investors are probably buying it recently.
Here, as implied by the title, I want to look at the best-case scenario, where in a few years investors might wish they had gotten in when the market cap was only in the low billions. In this scenario we go beyond the approval of Provenge for late-state metastatic, androgen-independent prostate cancer by the FDA some time in 2010. I believe approval by the FDA has already been fully-factored into the current price, at least by conservative, rational investors.
Provenge is an immunotherapy. There is no reason to think that its use cannot be extended to any prostate cancer that has antigen presenting cells (APCs) that can be activated with PAP (prostatic acid phosphatase). Or some similar method of stimulating a T cell response against prostate cancer cells, which is what Provenge does.
So while selling Provenge after FDA approval, the short term strategy for Dendreon is most likely to conduct more clinical trials that, if successful, will allow label extensions. Given Provenge's safety profile so far, and its ease-of-use (it requires just 3 infusions), it may become a blockbuster if it proves effective with earlier stages of prostate cancer.
Meanwhile, there is the pipeline Dendreon has already established. This includes Lapuleucel-T for breast, ovarian, and colon cancer. CEA for breast, lung, and colon cancer. And CA-9 for kidney, colon and cervical cancer. All three are immunotherapies, and only Lauleucel-T has started clinical trials. CEA and CA-9 are joined by Trp-p8 in being preclinical (lab/animal testing stage). The later is a small-molecule prostate therapy. I suppose they know a lot about prostate cancer now, and wanted a small-molecule as a hedge against the limitations of immunotherapy.
Developing a pipeline is a very long term process. It will probably take years to get any of the drugs already in the pipeline through FDA approval, and that is assuming the data is good. Figure 5 years for another approval, maybe 3 years under the most accelerated scenario. I know; most investors can't think that long term.
But look at the best case scenario ten years out. Dendreon could, by then, have brought out immunotherapies for all the major cancer types.
And therein lies the glory and the dream. Given the complexity of the human body, the immune system, and cancers, it is highly unlikely that immunotherapy will replace other cancer therapies. But given its safety (if it proves to be safe long-term), there is no reason not to try it on any and every cancer patient.
Just a hint of that scenario breaths life into Dendreon's stock price. We are talking truly big money. Others will accelerate their immunotherapy efforts, but Dendreon has a lead and will be generating revenues from Provenge that can be used to bring new immunotherapies to market.
What Dendreon owns is not just Provenge. It owns, and has protected with patents, a new type of technology. If the technology really works, Dendreon is not just a company. It is an industry in the making.
Keep diversified!
Labels:
Dendreon,
FDA,
immunotherapy,
pipeline,
prostate cancer,
Provenge,
sipuleucel-T
Wednesday, April 29, 2009
Provenge Prostate Cancer Data from Dendreon
Note: This was an analyst conference to discuss the release of data from the Provenge IMPACT clinical trial. This is a detailed summary, not a transcript of the full conference.
Overview: The data appears to be slightly stronger than the levels set by the FDA for the approval of Provenge for metastatic prostate cancer.
Highlights:
IMPACT Study met prespecified endpoints.
Data presented at American Urology Association conference. Average increase life time was 4.1 month. There was a 38% 3 year survival increase compared to placebo. 22% reduction of risk of death, or a Hazard ratio of 0.78. For the placebo arm median survival was 21.7 months, for Provenge it was 25.8 months.
Provenge is sipuleucel-T, an autologous active cellular immunotherapy against prostate cancer.
There were 512 asymptomatic or minimally symptomatic metastatic androgen independent prostate cancer patients in the study. Life expectancy at entry had to be at least 6 months. Castrate levels of testosterone had to be achieved. Statistical P value prespecified with FDA at <0.043. Actual P = 0.032
Ruled out the possibility that survival benefit was due to a subgroup difference with placebo group.
Multiple sensitivity analyses confirmed P values and Hazard ratios.
Time to progressive disease progression (secondary endpoint) was not statistically significant.
Safety profile was consistent with earlier results; mostly headaches, chills, and fever the day following treatment. Less than 10% developed influenza type symptoms, hypertension or hyperhydrosis (sweating). Placebos had 23.8% serious adverse events, Provenge arm 24.0%. But placebo arm had much less mild adverse events.
D9901, D9902A, and IMPACT study had every similar results. Integrating them all gave a Hazard ratio of 0.735, p value 0.001, median survival benefit 3.9 months, and 33% 36 month survival v. 20% for placebo.
Placebo arm survivors can now be given Provenge.
Will apply for licensing this year in U.S.
Conclusion: Results are unambiguous. First active immunotherapy to demonstrate overall survival. Highly favorable benefit to risk profile. Short therapy duration. Could create a new oncology treatment paradigm; platform could be applied across different cancers.
Q&A:
Why can’t you file sooner with FDA? This study has been going on almost 6 years. We need to put together the best amendment we can. It is a type 2 resubmission, giving the FDA 6 months to review it.
Other cancers? Will be evaluating, will update you this summer.
Why 3 infusion maximum? P11 study in early stage prostate cancer showed immune systems had a persistent response against antigen. Did get an increase with boosting infusion. This was 1999. There is no reason to not give more infusions, it was just not part of the study design.
Any side effects statistically significant? Yes, the ones listed were significant.
Median survival results for placebo crossing to Taxotere? Subgroup analysis can be misleading. But we believe there is a benefit to crossover arm.
Partnering for global sales? Our goal is to keep the product for ourselves in U.S. Get a partner ex-U.S. There has been a lot of interest, we have nothing to say so far.
Medians on time to progression? 14 weeks.
This study was not designed to be a comparison study of Taxotere (docetaxel). It has a 2.5 month survival improvement. So Provenge is safer and more effective, and requires less infusions.
Taxotere after Provenge data? We may get some data on that, but have nothing to share at this time.
PSAs were not measured after patients progressed. In androgen independent prostate cancer, PSA does not correlate with survival.
Trend in pain direction? Pain was not an end point after the study was amended.
Time to progression is a difficult to measure statistic, highly subjective. So it is an unreliable endpoint.
48 month rejoin of trends? All survival curves come together eventually. At the tail end of the curve there are very few living patients, so a lot of variability.
Link to Dendreon April 28, 2009 Press Release
My Dendreon Main Page
Overview: The data appears to be slightly stronger than the levels set by the FDA for the approval of Provenge for metastatic prostate cancer.
Highlights:
IMPACT Study met prespecified endpoints.
Data presented at American Urology Association conference. Average increase life time was 4.1 month. There was a 38% 3 year survival increase compared to placebo. 22% reduction of risk of death, or a Hazard ratio of 0.78. For the placebo arm median survival was 21.7 months, for Provenge it was 25.8 months.
Provenge is sipuleucel-T, an autologous active cellular immunotherapy against prostate cancer.
There were 512 asymptomatic or minimally symptomatic metastatic androgen independent prostate cancer patients in the study. Life expectancy at entry had to be at least 6 months. Castrate levels of testosterone had to be achieved. Statistical P value prespecified with FDA at <0.043. Actual P = 0.032
Ruled out the possibility that survival benefit was due to a subgroup difference with placebo group.
Multiple sensitivity analyses confirmed P values and Hazard ratios.
Time to progressive disease progression (secondary endpoint) was not statistically significant.
Safety profile was consistent with earlier results; mostly headaches, chills, and fever the day following treatment. Less than 10% developed influenza type symptoms, hypertension or hyperhydrosis (sweating). Placebos had 23.8% serious adverse events, Provenge arm 24.0%. But placebo arm had much less mild adverse events.
D9901, D9902A, and IMPACT study had every similar results. Integrating them all gave a Hazard ratio of 0.735, p value 0.001, median survival benefit 3.9 months, and 33% 36 month survival v. 20% for placebo.
Placebo arm survivors can now be given Provenge.
Will apply for licensing this year in U.S.
Conclusion: Results are unambiguous. First active immunotherapy to demonstrate overall survival. Highly favorable benefit to risk profile. Short therapy duration. Could create a new oncology treatment paradigm; platform could be applied across different cancers.
Q&A:
Why can’t you file sooner with FDA? This study has been going on almost 6 years. We need to put together the best amendment we can. It is a type 2 resubmission, giving the FDA 6 months to review it.
Other cancers? Will be evaluating, will update you this summer.
Why 3 infusion maximum? P11 study in early stage prostate cancer showed immune systems had a persistent response against antigen. Did get an increase with boosting infusion. This was 1999. There is no reason to not give more infusions, it was just not part of the study design.
Any side effects statistically significant? Yes, the ones listed were significant.
Median survival results for placebo crossing to Taxotere? Subgroup analysis can be misleading. But we believe there is a benefit to crossover arm.
Partnering for global sales? Our goal is to keep the product for ourselves in U.S. Get a partner ex-U.S. There has been a lot of interest, we have nothing to say so far.
Medians on time to progression? 14 weeks.
This study was not designed to be a comparison study of Taxotere (docetaxel). It has a 2.5 month survival improvement. So Provenge is safer and more effective, and requires less infusions.
Taxotere after Provenge data? We may get some data on that, but have nothing to share at this time.
PSAs were not measured after patients progressed. In androgen independent prostate cancer, PSA does not correlate with survival.
Trend in pain direction? Pain was not an end point after the study was amended.
Time to progression is a difficult to measure statistic, highly subjective. So it is an unreliable endpoint.
48 month rejoin of trends? All survival curves come together eventually. At the tail end of the curve there are very few living patients, so a lot of variability.
Link to Dendreon April 28, 2009 Press Release
My Dendreon Main Page
Labels:
Dendreon,
FDA,
immunotherapy,
prostate cancer,
Provenge,
sipuleucel-T
Sunday, September 14, 2008
Dendreon Provenge Prostate Cancer Results Due Soon
October 2008 may bring the epic saga of Dendreon's immunotherapy for prostate cancer, Provenge, to an end. Or it might open up a bright new era in the fight against cancer.
For a full recap of the epic so far, see my Dendreon Provenge page.
This is a time of fear and greed for investors. Although technically the expected October announcement (but don't be too surprised if there are further delays) is for interim results of the FDA-mandated trials of Provenge, Dendreon has gone to great lengths to insure that the interim results will be a solid basis for acceptance by the FDA, which means they are also a solid basis for rejection by the FDA. The band where it makes sense to wait for the final results (which might not be available until 2010) is probably quite narrow. If Dendreon does not have passing interim results, in my estimate their intellectual property, and their stock value, is nearly worthless. On the other hand, passing results means they own among the world's most valuable biotechnology intellectual property. They will be able to ramp up Provenge sales quickly and also ramp up studies of their immunotherapy methods for a variety of other cancers.
One thing that many investors don't understand, and that even professional analysts and scientists forget, is just how much of a dice roll these kinds of study results amount to. We tend to think of science based on the physics paradigm, where frictionless, idealized masses follow trajectories fixed by known momentum and outside forces. But clinical therapy trials (Provenge is not a drug, but an activation system for the immune system) seldom give black and white answers. A percentage of patients responds; a percentage of patients have adverse reactions; a percentage of patients do not respond. Whether the response rate compared to the adverse reaction rate makes a therapy worthwhile of FDA approval is the whole game.
You have two separate sources of randomness at work in such trials. One is the mathematical randomness. This is of the sort that gives you those plus-or-minus 3% footnotes in political poles. In theory the larger the number of subjects, the smaller the likely randomness of the final result. Polling 500 people or testing 500 patients does not give us as much confidence in our results as polling 2000 people or testing 2000 patients.
In effect, when FDA did not approve Provenge on its first submission, but saying Provenge could be approvable with more data, the FDA was saying that the original sample size was not big enough. On the other hand, if the results for the patients had been better, the sample size would have been big enough.
The other kind of randomness is the innate randomness of biological systems. Patients are not all alike. They differ not only in age, sex, and degree of illness, but in general health, in specific DNA makeup, and in all sorts of microscopic manners. In particular 500 patients may be believed to have the same type of cancer (prostate, in our case), but those cancers may differ in ways that are significant but not understood.
I once saw a combined study of over a dozen clinical trials. In theory each trial was looking at the same drug for the same disease. Yet in some of the trials the drug appeared to be a failure, in some it appeared to be a success, and in some results were marginal. Aggregated the data showed the drug was valuable, but if one of the failed tests was all a company had to show to the FDA, there would be no approval.
So the risk, both upside and downside, for Dendreon investors is hard to quantify. No one can really do more than estimate how much real world variation could affect the Provenge trial.
Management says that if Provenge simply does as well as it did in earlier trials, the FDA will approve it. I don't doubt that (though the FDA does not have to keep such a promise). What I know is that random fluctuations can be significant in clinical trials, even in large scale ones. So I don't seen good results as guaranteed. Balancing that, results could also be better than expected, which would go a long way to helping market the drug.
Provenge is very safe, so it has almost no down side risk. I believe any benefit it shows for men with prostate cancer should earn it approval. But I am not sitting on the FDA; that committee may think differently.
I own Dendreon stock. But in biotechnology stocks it is always best to ...
Keep diversified!
More data:
www.dendreon.com
Dendreon August 12, 2008 Analyst Conference summary
For a full recap of the epic so far, see my Dendreon Provenge page.
This is a time of fear and greed for investors. Although technically the expected October announcement (but don't be too surprised if there are further delays) is for interim results of the FDA-mandated trials of Provenge, Dendreon has gone to great lengths to insure that the interim results will be a solid basis for acceptance by the FDA, which means they are also a solid basis for rejection by the FDA. The band where it makes sense to wait for the final results (which might not be available until 2010) is probably quite narrow. If Dendreon does not have passing interim results, in my estimate their intellectual property, and their stock value, is nearly worthless. On the other hand, passing results means they own among the world's most valuable biotechnology intellectual property. They will be able to ramp up Provenge sales quickly and also ramp up studies of their immunotherapy methods for a variety of other cancers.
One thing that many investors don't understand, and that even professional analysts and scientists forget, is just how much of a dice roll these kinds of study results amount to. We tend to think of science based on the physics paradigm, where frictionless, idealized masses follow trajectories fixed by known momentum and outside forces. But clinical therapy trials (Provenge is not a drug, but an activation system for the immune system) seldom give black and white answers. A percentage of patients responds; a percentage of patients have adverse reactions; a percentage of patients do not respond. Whether the response rate compared to the adverse reaction rate makes a therapy worthwhile of FDA approval is the whole game.
You have two separate sources of randomness at work in such trials. One is the mathematical randomness. This is of the sort that gives you those plus-or-minus 3% footnotes in political poles. In theory the larger the number of subjects, the smaller the likely randomness of the final result. Polling 500 people or testing 500 patients does not give us as much confidence in our results as polling 2000 people or testing 2000 patients.
In effect, when FDA did not approve Provenge on its first submission, but saying Provenge could be approvable with more data, the FDA was saying that the original sample size was not big enough. On the other hand, if the results for the patients had been better, the sample size would have been big enough.
The other kind of randomness is the innate randomness of biological systems. Patients are not all alike. They differ not only in age, sex, and degree of illness, but in general health, in specific DNA makeup, and in all sorts of microscopic manners. In particular 500 patients may be believed to have the same type of cancer (prostate, in our case), but those cancers may differ in ways that are significant but not understood.
I once saw a combined study of over a dozen clinical trials. In theory each trial was looking at the same drug for the same disease. Yet in some of the trials the drug appeared to be a failure, in some it appeared to be a success, and in some results were marginal. Aggregated the data showed the drug was valuable, but if one of the failed tests was all a company had to show to the FDA, there would be no approval.
So the risk, both upside and downside, for Dendreon investors is hard to quantify. No one can really do more than estimate how much real world variation could affect the Provenge trial.
Management says that if Provenge simply does as well as it did in earlier trials, the FDA will approve it. I don't doubt that (though the FDA does not have to keep such a promise). What I know is that random fluctuations can be significant in clinical trials, even in large scale ones. So I don't seen good results as guaranteed. Balancing that, results could also be better than expected, which would go a long way to helping market the drug.
Provenge is very safe, so it has almost no down side risk. I believe any benefit it shows for men with prostate cancer should earn it approval. But I am not sitting on the FDA; that committee may think differently.
I own Dendreon stock. But in biotechnology stocks it is always best to ...
Keep diversified!
More data:
www.dendreon.com
Dendreon August 12, 2008 Analyst Conference summary
Labels:
biotechnology,
cancer,
Dendreon,
FDA,
immunotherapy,
prostate cancer,
Provenge
Subscribe to:
Posts (Atom)
